Abstract: The mouse is becoming an increasingly attractive model for auditory research due to the number of genetic deafness models available. These genetic models offer the researcher an array of congenital causes of hearing impairment, and are therefore of high clinical relevance. To date, the use of mice in cochlear implant research has not been possible due to the lack of an intracochlear electrode array and stimulator small enough for murine use, coupled with the difficulty of the surgery in this species. Here, we present a fully-implantable intracochlear electrode stimulator assembly designed for chronic implantation in the mouse. We describe the surgical approach for implantation, as well as presenting the first functional data obtained from chronic intracochlear electrical stimulation in the mouse.
Mouse paper highlights:
 We describe a procedure for cochlear implantation in the mouse  The first functional data for intracochlear electrical stimulation in the mouse is presented  Normal-hearing mice are successfully deafened using neomycin  Chronic cochlear implantation and electrical stimulation can be performed in mice  Cauterising the stapedial artery has no effect on hearing thresholds in mice *Highlights (for review)
Abstract

21
The mouse is becoming an increasingly attractive model for auditory research due to the 22 number of genetic deafness models available. These genetic models offer the researcher an 23 array of congenital causes of hearing impairment, and are therefore of high clinical relevance. 24
To date, the use of mice in cochlear implant research has not been possible due to the lack of an 25 intracochlear electrode array and stimulator small enough for murine use, coupled with the 26 difficulty of the surgery in this species. Here, we present a fully-implantable intracochlear 27 electrode stimulator assembly designed for chronic implantation in the mouse. We describe the 28 surgical approach for implantation, as well as presenting the first functional data obtained from 29 intracochlear electrical stimulation in the mouse. with intracochlear electrical stimulation would provide critical information on the mechanisms 51 of electrical stimulation in the cochlea. To date, no method has enabled the delivery of chronic 52 electrical stimulation to the mouse cochlea, primarily due to the absence of a reliable electrode-53 stimulator assembly small enough for chronic murine use, and the difficulty of the implantation 54 surgery in such a comparatively small cochlea. To compound this surgical difficulty, the mouse, 55 like the rat (Lu et al., 2005) , has a stapedial artery (SA) that runs inside the middle ear cavity 56 close to the round window (RW) niche, reducing surgical access to the cochlea and increasing 57
surgical risk 58
We describe the procedure for cochlear implantation of an electrode array in the mouse, with 59 our custom-designed fully-implantable small rodent stimulator (Millard and Shepherd, 2007) . 60
We also discuss the need for cauterizing the SA, present functional recordings during 61 intracochlear electrical stimulation, and present histological analysis of cochlear tissue 62 implanted with this device. 63
Methods
65
All procedures were approved by the Royal Victorian Eye and Ear Hospital animal research 66
Ethics Committee in accordance with the Australian National Health and Medical Research 67
Council's animal experimentation guidelines. 68
Subjects
70
Development of the mouse cochlear implant required a robust animal model that could undergo 71 cochlear implantation in order to optimise the surgical approach and confirm functional 72 activation of the auditory pathway. To this end, C57BL/6 adult mice (n=29) aged 8-10 weeks 73 (weight 20-30 g) were used in this study. Individual animals were divided into experimental 74 groups, undergoing the procedures indicated in Table 1 
Electrode array and stimulator
84
The fully-implantable stimulator has been described previously (Millard and Shepherd, 2007) . 85
Briefly, the stimulator consisted of an electromagnetic coil (Sonion; Passive Telecoil T20 AG 12, 86 9012-1050184), a bi-directional current regulator, a capacitor and bipolar electrodes (Figure 1) . 87
The stimulator was encapsulated in conformal coating and medical grade silicone to prevent 88 ingress of fluid, was compact (3 x 10 mm), and weighed less than 1 g (~3% of the weight of an 89 adult mouse), offering minimal hindrance to the implanted animal. 90
91
[FIGURE 1 ABOUT HERE] 92
93
The stimulator was driven by an external magnetic field that induced current through the 94 current regulator and capacitor to the electrodes situated inside the cochlea. The magnetic field 95 was provided by an excitation coil assembly (not shown; see Millard and Shepherd 2007), 96 composed of three orthogonal coils around an animal enclosure, which allowed the animal to 97 move freely during stimulation. The stimulator produced charge-balanced biphasic current 98 pulses with fixed amplitude. As the current produced by the stimulator circuit was constant, the 99 delivered charge was determined by the width of the magnetic pulse and subsequent current 100 pulse (25-250 µs). To prevent undesirable build-up of charge, the electrodes were shorted 101 between stimuli when the coils were not excited. Pulse width and stimulation rate (50-5000 Hz) 102
were varied using a computer-controlled external control unit. 103
The intracochlear electrode array consisted of four 0.2 mm diameter platinum bands spaced at 104 0.4 mm intervals (Figure 2 ). The electrode array was designed to have 3 intracochlear 105 electrodes and a platinum marker used as an extracochlear reference during insertion. For the 106 purpose of this study, only the tip and third bands were attached to the stimulator, via helical 107 platinum leadwires embedded in a silicone carrier. This configuration allowed delivery of 'wide' 108 bipolar stimulation. Once assembled, the implant, leadwire, and stimulator assembly was 70 109 mm in length (Figure 2 ). The leadwire helix was narrowest at the tip (diameter 0.2 mm) and 110 tapered out over 1 cm to its maximal diameter (~0.8 mm) to enable intracochlear insertion and 111 coiling inside the bulla (see Figure 3) . After the taper, the leadwire diameter increased to ~1 112 mm to improve the robustness of the device. A Dacron mesh (Invista, USA) flange was placed 113 30 mm from the tip of the leadwire and another piece of Dacron was also used to cover the 114 stimulator to encourage tissue adhesion and limit movement of the device under the skin 115 retracted to reveal the facial nerve extending over the bulla. Under a surgical microscope, the 131 tissue overlying the medio-dorsal area of the bulla was removed with a bone-scraper to allow 132 clear visualization of the ridge between the bulla and the mastoid process ( Figure 3A) . A 0.6 mm 133 diameter diamond burr was then used to expose the middle ear cavity, taking care not to 134 damage the SA ( Figure 3B) The mouse has a relatively large SA within the middle ear, running ventral to the RW niche 142 (Figure 3B ), which can cause a fatal bleeding hazard during implantation via the RW. The effects 143 of cauterizing the SA in the mouse have not previously been described, but research in the rat, 144 which also has a prominent SA overlying the RW niche, has shown no adverse effects on hearing 145 thresholds or spiral ganglion neuron survival (SGN; Lu, Xu et al., 2005) . In order to determine 146 the effects of cauterizing the SA on hearing thresholds and SGN survival in the mouse, the SA 147 was cauterized in 5 animals. The surgical approach was similar to that described in the rat by Lu 148 and colleagues (2005): the bullostomy was drilled as above, the SA was then cauterized within 149 the bulla using bipolar cautery forceps. The bulla was then closed with sterile polycarboxylate 150 cement (Durelon, ESPE, Norristown, USA), and the wound closed in two layers using an 151 absorbable 6/0 suture. Four weeks following surgery, an ABR was recorded to assess the effects 152 of the procedure on hearing. 153 As C57BL/6 mice have normal hearing we developed a deafening technique for use in 154 combination with the fully implantable stimulator. In order to quantify the effects of this 155 deafening technique on hearing thresholds and SGN survival, 6 animals were deafened 156 unilaterally using the ototoxic aminoglycoside neomycin. The surgical approach was identical to 157 that presented above, including cauterizing the SA. The RW membrane was then perforated 158 using a probe, and perilymph was slowly aspirated. Concentrations of either 5% or 10% 159 weight/volume neomycin (n = 3/cohort) were then slowly perfused through the RW. Next, a 1 160 
Chronic implantation
182
The implantation of the chronic stimulation assembly ( Figure 2 ) followed the same steps 183 detailed above (including cautery of the SA), up to and including slow intra-cochlear perfusion 184 of 5% neomycin. At this stage, the chronic electrode array was inserted as above, and the 185 leadwire was curled inside the bulla ( Figure 3D ) and fixed in place using polycarboxylate 186 cement. A subcutaneous pocket was blunt-dissected from the scapula down to the area above 187 the hind leg, which was shaped to house the stimulator and leadwire without any tension 188 
Electrically-evoked auditory brainstem responses (EABR)
218
To confirm successful stimulation of the auditory pathway by the intracochlear electrode array, 219
EABRs were recorded using a laboratory stimulator in the 4 animals that received an acute 220 implant. The recording of EABRs has been described elsewhere in guinea pig (Landry et al., To determine electrical threshold in animals implanted with the fully implantable mouse 232 stimulator assembly, magnetically-induced EABRs (mEABRs) were recorded one week after 233 surgery. Additional mEABRs were recorded at the end of the 4-week experimental period to 234 confirm the correct functioning of the fully implanted device. This procedure is detailed in 235 were the same as EABRs, with the addition that the animal was placed within a small tube 237 surrounded by a single electro-magnetic coil to cover and drive the implanted stimulator (note: 238 this differs from the excitation coil stimulating enclosure used to provide chronic stimulation). 239
The animal's head and the recording electrodes remained outside of the magnetic field to 240 minimise interference. Charge delivery was controlled by varying the duration of the stimulus 241 phase (e.g. 15-100 µs in 5 µs steps) via a custom IgorPro procedure. Recording procedures 242
were the same as for EABRs. mEABRs were successfully obtained in each of the 3 animals in the 243 chronic stimulation group. 244 245
Chronic Stimulation
247
Chronic electrical stimulation was carried out in 3 mice (Table 1) . Animals were placed, awake, 248 within the excitation coil stimulating enclosure and stimulated at up to 6 dB above their mEABR 249 threshold for 4 hours/day for up to one month. 250 251
Histological analysis 252 253
After the final functional recording, each animal was euthanized with an overdose of lethabarb 254 (Virbac, Milperra, Australia; 150mg/kg) and systemically perfused using 20 ml of 10% neutral 255 buffered formalin (NBF). Both cochleae were dissected, the oval window perforated and the 256 cochleae postfixed for 2 hours, followed by 3 washes in 0.1 M phosphate buffered solution 257 (PBS). Cochleae were then decalcified in 4 % ethylenediamine tetraacetic acid (EDTA) in 0.1 M 258 PBS before cryoprotecting in 15% and then 30% sucrose. Cochleae were subsequently 259 All animals in the SA cautery group displayed click-evoked ABR waveforms before and 4 weeks 308 after surgery (e.g. Figure 5 ), and although increases in ABR threshold were observed in the left 309 experimental ear in some animals (up to 40 dB HL), others did not exhibit increased thresholds 310 (mean thresholds shift: 21 dB HL ± 9.5). SA cautery was successful in all cases (Figure 6 ). There 311 was some evidence of heat/surgical damage to the cochlea in some animals, which may have 312 contributed to the increased ABR thresholds. This could be avoided by further surgical 313 refinement. In order to determine the significance of the shift in ABR threshold pre-and post-SA 314 cauterization with this non-normal distribution, a Wilcoxon test was carried out, which 315 indicated that the threshold shift was non-significant (p = .102). There was also no significant 316 difference between ABR thresholds on the left (experimental) and right (control) sides for this 317 group, either pre-(p = 0.37) or post-SA cautery (p = 0.141). As expected from the lack of 318 significant changes in ABR threshold, cauterizing the SA did not affect SGN densities, compared 319 to the uncauterized control ear, in either the base (p = 0.68) or the apex (p = 0.34) of the cochlea 320 (Table 2) . 
Effects of neomycin deafening
328
Animals deafened with 5% and 10% neomycin, combined with SA cauterization, showed 329 significant increases in click-evoked hearing thresholds for the experimental cochlea (pre-vs. 330 post-surgery; 5% neomycin: 41.6 dB ± 3.3 to 76.6 dB ± 4.4, p = 0.02; 10% neomycin: 48.3 dB ± 6 331 to > 100 dB p = 0.006 respectively; an average of 35 dB HL for 5% and 58.3 dB HL for 10%). For 332 5% neomycin, the contralateral ear did not display a significant change in threshold (p > 0.5), 333 but 10% neomycin caused significantly increased thresholds in the contralateral, non-334 experimental ear for the 3 animals in this group (p = 0.018). This loss of hearing suggests some 335 transit of the drug at higher concentration to the contralateral cochlea, although the increase in 336 threshold was not as pronounced as that in the treated ear (p = 0.004). Interestingly, despite the 337 significant increases in hearing thresholds with the use of neomycin, there was no significant 338 decrease in SGN densities between treated and untreated contralateral control cochleae at 339 either the base (Table 2 ; 5%: p = 0.25; 10%: p = 0.33) or the apex (Table 2 ; 5%: p = 0.3; 10%: p = 340 0.14) four weeks post-deafening. Furthermore, no evidence of tissue response was seen in these 341 animals. Due to the bilateral, but asymmetric hearing loss caused by the higher concentration 342 (10%), 5% neomycin was used in all mice detailed below to ensure that ABR thresholds in the 343 contralateral cochlea were unimpaired. 344 
Chronic ES of the mouse cochlea
372
The response of the mouse cochlea to chronic ES was evaluated by the examination of the tissue 373 response and SGN survival in the 3 chronically treated animals. These results are presented 374 below and in Table 2 for unstimulated controls and chronically stimulated animals. 375
1) Chronic implantation: unstimulated 376 377
Unstimulated implanted control animals exhibited a fibrous tissue response and new bone 378 growth in the implanted cochlea ( Figure 9A ), which was quantified by determining the area of 379 scala tympani that it occupied. This response was primarily located in the basal turns 380 (encompassing 52% of ST; ± 7.9%), with 40% of ST (±7.3) representing new bone growth and 381 12% of ST as fibrous tissue, although some tissue response was also seen in the middle turn in 2 382 animals. SGN densities were comparable to those seen in animals in the 5% neomycin group (p 383 > 0.05; Table 2 ), suggesting that implantation per se was not detrimental to SGN survival over a 384 1 month period. However, more animals are required to confirm that this is the case. The latter were notably higher than the functional mEABR thresholds, meaning that chronic 457 stimulation was presented above the electrophysiological threshold without evoking myogenic 458
activity. 459
We saw no evidence of stimulus-induced SGN rescue in the three chronically-stimulated animals 460 Resistor. The implantable stimulator was driven by an external magnetic coil assembly (not shown) which induced charge-balanced biphasic current pulses in response to a pulsed magnetic field, and pulse width and stimulation rates were varied using a computer-controlled external control unit. 
